Research programme: PDZ domain inhibitors - Avilex Pharma
Latest Information Update: 16 Jul 2016
At a glance
- Originator Avilex Pharma
- Mechanism of Action PDZ domain inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neuropathic-pain in Denmark
- 15 Apr 2013 Early research in Neuropathic pain in Denmark (unspecified route)